# Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/glycemic-durability-of-rosiglitazone-metformin-or-glyburide-monotherapy/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Steven E. Kahn,Steven M. Haffner,Mark Heise,William H. Herman,Rury R. Holman,Nigel C. Jones,Barbara G. Kravitz,John M. Lachin,Mark O’Neill,Bernard Zinman,Giancarlo Viberti |
| Citations | 2,958 |
| DOI | 10.1056/nejmoa066224 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2081276121 |
| PMID | 17145742 |
| Type | article |
| Year | 2006 |

## Paper authors

- [Steven E. Kahn](https://scholariq.org/researchers/steven-e-kahn/)
- [John M. Lachin](https://scholariq.org/researchers/john-m-lachin/)
- [Rury R. Holman](https://scholariq.org/researchers/rury-r-holman/)
- [William H. Herman](https://scholariq.org/researchers/william-h-herman/)
- [Bernard Zinman](https://scholariq.org/researchers/bernard-zinman/)

## Paper journal

- [New England Journal of Medicine](https://scholariq.org/journals/new-england-journal-of-medicine/)

## Paper primary topic

- [Peroxisome Proliferator-Activated Receptors](https://scholariq.org/topics/peroxisome-proliferator-activated-receptors/)

## Paper topics

- [Peroxisome Proliferator-Activated Receptors](https://scholariq.org/topics/peroxisome-proliferator-activated-receptors/)
- [Diabetes, Cardiovascular Risks, and Lipoproteins](https://scholariq.org/topics/diabetes-cardiovascular-risks-and-lipoproteins/)
- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.